CL2007003049A1 - Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos. - Google Patents
Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos.Info
- Publication number
- CL2007003049A1 CL2007003049A1 CL200703049A CL2007003049A CL2007003049A1 CL 2007003049 A1 CL2007003049 A1 CL 2007003049A1 CL 200703049 A CL200703049 A CL 200703049A CL 2007003049 A CL2007003049 A CL 2007003049A CL 2007003049 A1 CL2007003049 A1 CL 2007003049A1
- Authority
- CL
- Chile
- Prior art keywords
- diaminopirimidine
- useful
- pharmaceutical composition
- proliferative disorders
- compounds derived
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85356206P | 2006-10-23 | 2006-10-23 | |
| PCT/US2007/022496 WO2008051547A1 (en) | 2006-10-23 | 2007-10-23 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2007003049A1 true CL2007003049A1 (es) | 2008-05-16 |
Family
ID=39050187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL200703049A CL2007003049A1 (es) | 2006-10-23 | 2007-10-23 | Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8148391B2 (es) |
| EP (2) | EP2684874B1 (es) |
| JP (1) | JP5512274B2 (es) |
| CN (1) | CN101535276B (es) |
| AR (1) | AR063527A1 (es) |
| AU (1) | AU2007309427B2 (es) |
| CA (1) | CA2669111C (es) |
| CL (1) | CL2007003049A1 (es) |
| ES (2) | ES2555803T3 (es) |
| HK (1) | HK1147748A1 (es) |
| IL (1) | IL198150A (es) |
| MX (1) | MX2009004426A (es) |
| NZ (1) | NZ576425A (es) |
| TW (1) | TWI432427B (es) |
| WO (1) | WO2008051547A1 (es) |
Families Citing this family (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| US8710045B2 (en) * | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
| WO2008051547A1 (en) * | 2006-10-23 | 2008-05-02 | Cephalon, Inc. | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors |
| NZ577197A (en) | 2006-12-08 | 2011-02-25 | Irm Llc | Pyrimidine compounds especially 4-phenylamino-2-arylamino-pyrimidine derivatives and compositions as protein kinase inhibitors |
| DK2091918T3 (en) * | 2006-12-08 | 2014-12-01 | Irm Llc | Compounds and Compositions as Protein Kinase Inhibitors |
| EP2727909A1 (en) * | 2007-03-16 | 2014-05-07 | The Scripps Research Institute | Inhibitors of focal adhesion kinase |
| TWI389893B (zh) | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二（芳胺基）芳基化合物 |
| EP2190826A2 (en) * | 2007-08-28 | 2010-06-02 | Irm Llc | 2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors |
| WO2009122180A1 (en) * | 2008-04-02 | 2009-10-08 | Medical Research Council | Pyrimidine derivatives capable of inhibiting one or more kinases |
| KR101238585B1 (ko) | 2008-04-07 | 2013-02-28 | 노파르티스 아게 | 단백질 키나제 억제제로서의 화합물 및 조성물 |
| WO2009127642A2 (en) * | 2008-04-15 | 2009-10-22 | Cellzome Limited | Use of lrrk2 inhibitors for neurodegenerative diseases |
| US8063058B2 (en) | 2008-04-16 | 2011-11-22 | Portola Pharmaceuticals, Inc. | Inhibitors of syk and JAK protein kinases |
| US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| EP3210609A1 (en) | 2008-05-21 | 2017-08-30 | Ariad Pharmaceuticals, Inc. | Phosphorous derivatives as kinase inhibitors |
| PE20100087A1 (es) | 2008-06-25 | 2010-02-08 | Irm Llc | Compuestos y composiciones como inhibidores de cinasa |
| US8445505B2 (en) | 2008-06-25 | 2013-05-21 | Irm Llc | Pyrimidine derivatives as kinase inhibitors |
| SI2889033T1 (en) | 2008-11-19 | 2018-08-31 | Forum Pharmaceuticals Inc. | Treatment of negative symptoms of schizophrenia with (R) -7-chloro-N- (chonylidin-3-yl) benzo (B) thiophene-2-carboxamide and pharmaceutically acceptable salts thereof |
| MX2011005898A (es) | 2008-12-03 | 2011-09-27 | Presidio Pharmaceuticals Inc | Inhibidores de la proteina no estructural 5a del virus de la hepatitis c. |
| US20110071158A1 (en) * | 2009-03-18 | 2011-03-24 | Boehringer Ingelheim International Gmbh | New compounds |
| CN102421761B (zh) | 2009-05-08 | 2014-06-18 | 安斯泰来制药株式会社 | 二氨基杂环甲酰胺化合物 |
| PE20120324A1 (es) * | 2009-05-11 | 2012-04-17 | Envivo Pharmaceuticals Inc | Combinacion que comprende (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y donezepilo como moduladora de trastornos cognitivos |
| TW201100441A (en) * | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
| EP2440534A2 (en) * | 2009-06-10 | 2012-04-18 | Cellzome Limited | Pyrimidine derivatives as zap-70 inhibitors |
| US9126931B2 (en) * | 2009-06-10 | 2015-09-08 | Chugai Seiyaku Kabushiki Kaisha | Tetracyclic compound |
| SI2464645T1 (sl) | 2009-07-27 | 2017-10-30 | Gilead Sciences, Inc. | Zlite heterociklične spojine kot ionsko kanalni modulatorji |
| EP2464633A1 (en) | 2009-08-14 | 2012-06-20 | Boehringer Ingelheim International GmbH | Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives |
| US8933227B2 (en) | 2009-08-14 | 2015-01-13 | Boehringer Ingelheim International Gmbh | Selective synthesis of functionalized pyrimidines |
| CA2779088A1 (en) * | 2009-11-16 | 2011-05-19 | Mellitech | [1,5]-diazocin derivatives |
| CA2989633A1 (en) | 2010-05-17 | 2011-11-24 | Forum Pharmaceuticals Inc. | A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate |
| WO2012003338A1 (en) | 2010-07-01 | 2012-01-05 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
| BR112012033402A2 (pt) | 2010-07-02 | 2017-01-24 | Gilead Sciences Inc | moduladores de canais de íons conforme os compostos heterocíclicos fundidos |
| WO2012019132A2 (en) | 2010-08-06 | 2012-02-09 | Cell Signaling Technology, Inc. | Anaplastic lymphoma kinase in kidney cancer |
| CN103052386B (zh) | 2010-08-20 | 2016-03-02 | 中外制药株式会社 | 含有四环化合物的组合物 |
| JP5006987B2 (ja) * | 2010-11-22 | 2012-08-22 | 中外製薬株式会社 | ４環性化合物を含む医薬 |
| JP6000273B2 (ja) | 2010-11-29 | 2016-09-28 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 大環状キナーゼ阻害剤 |
| BR112013027734A2 (pt) | 2011-05-04 | 2017-08-08 | Ariad Pharma Inc | compostos para a inibição de proliferação celular em cânceres impulsionados pelo egfr, método e composição farmacêutica |
| BR112013028886A2 (pt) | 2011-05-10 | 2016-08-09 | Gilead Sciences Inc | compostos heterocíclicos fundidos como moduladores dde canal de sódio |
| UY34171A (es) | 2011-07-01 | 2013-01-31 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como moduladores del canal iónico |
| NO3175985T3 (es) | 2011-07-01 | 2018-04-28 | ||
| EP2554544A1 (en) * | 2011-08-01 | 2013-02-06 | Almirall, S.A. | Pyridin-2(1h)-one derivatives as jak inhibitors |
| KR102019530B1 (ko) | 2011-11-23 | 2019-09-06 | 포톨라 파마슈티컬스, 인코포레이티드 | 피라진 키나아제 저해제 |
| MX348606B (es) * | 2011-11-29 | 2017-06-21 | Genentech Inc | Derivados de aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2). |
| HUE027976T2 (en) | 2012-03-06 | 2016-11-28 | Cephalon Inc | Condensed ring bicyclic 2,4-diaminopyrimidine derivative as dual ALK and FAK inhibitor |
| JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物 |
| AU2013259871A1 (en) | 2012-05-08 | 2014-11-20 | Forum Pharmaceuticals Inc. | Methods of maintaining, treating or improving cognitive function |
| KR101446742B1 (ko) | 2012-08-10 | 2014-10-01 | 한국화학연구원 | Ｎ2,ｎ4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| CN103664903A (zh) * | 2012-09-04 | 2014-03-26 | 中国科学院上海药物研究所 | 苯氮卓类化合物及其制备方法和用途 |
| MY170904A (en) | 2012-09-25 | 2019-09-13 | Chugai Pharmaceutical Co Ltd | Ret inhibitor |
| US9206166B2 (en) * | 2012-11-06 | 2015-12-08 | SHANGHAI iNSTITUTE OF MATERIA MEDICA ACADEMY OF SCIENCES | Certain protein kinase inhibitors |
| CN104968667B (zh) * | 2013-02-05 | 2017-06-20 | 山东轩竹医药科技有限公司 | 四并环激酶抑制剂 |
| KR20150118159A (ko) | 2013-02-22 | 2015-10-21 | 에프. 호프만-라 로슈 아게 | 암의 치료 방법 및 약물 내성의 예방 방법 |
| CA2905993C (en) | 2013-03-14 | 2022-12-06 | Tolero Pharmaceuticals, Inc. | Substituted 4-amino-pyrimidinyl-2-amino-phenyl derivatives and pharmaceutical compositions thereof for use as jak2 and alk2 inhibitors |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| JP2016522247A (ja) | 2013-06-18 | 2016-07-28 | ノバルティス アーゲー | 組合せ医薬 |
| WO2015038868A1 (en) * | 2013-09-13 | 2015-03-19 | Cephalon, Inc. | Fused bicyclic 2,4-diaminopyrimidine derivatives |
| KR101656382B1 (ko) | 2014-02-28 | 2016-09-09 | 한국화학연구원 | 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물 |
| MX2016013735A (es) | 2014-04-25 | 2017-03-09 | Chugai Pharmaceutical Co Ltd | Cristales novedosos de compuesto tetraciclico. |
| TWI720943B (zh) | 2014-04-25 | 2021-03-11 | 日商中外製藥股份有限公司 | 以高用量含有４環性化合物的製劑 |
| EP3140298A1 (en) | 2014-05-07 | 2017-03-15 | Pfizer Inc. | Tropomyosin-related kinase inhibitors |
| KR101881886B1 (ko) * | 2014-05-30 | 2018-07-25 | 베이징 피어 바이오테크놀로지 리미티드 라이어빌리티 컴페니 | Alk 키나제 억제제, 이의 제조방법 및 이의 용도 |
| US10053458B2 (en) * | 2014-06-17 | 2018-08-21 | Korea Research Institute Of Chemical Technology | Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient |
| TWI718102B (zh) | 2014-08-08 | 2021-02-11 | 日商中外製藥股份有限公司 | ４環性化合物的非晶質體 |
| KR101633722B1 (ko) | 2014-10-08 | 2016-06-28 | 한국화학연구원 | 4-(1-퍼롤-3,4-디카르복시아미드)피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| CN105524045B (zh) * | 2014-10-22 | 2020-04-10 | 山东轩竹医药科技有限公司 | 四环类间变性淋巴瘤激酶抑制剂 |
| EP3227263B1 (en) | 2014-12-01 | 2019-04-10 | Idorsia Pharmaceuticals Ltd | Cxcr7 receptor modulators |
| EP3229836B1 (en) | 2014-12-09 | 2019-11-13 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Human monoclonal antibodies against axl |
| WO2016100711A1 (en) * | 2014-12-18 | 2016-06-23 | The Broad Institute, Inc. | Modulators of hepatic lipoprotein metabolism |
| CN107249639B (zh) | 2015-01-16 | 2021-05-18 | 中外制药株式会社 | 联用药物 |
| WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
| KR101772134B1 (ko) | 2015-04-14 | 2017-08-29 | 한국화학연구원 | N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| KR101653571B1 (ko) | 2015-04-22 | 2016-09-05 | 한국화학연구원 | 4-(2-아미노-테트라하이드로나프탈렌닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| CN105400143B (zh) * | 2015-12-11 | 2017-10-03 | 广州欣凯化工科技有限公司 | 一种木制品缝隙的修补组合物 |
| MX2018008653A (es) | 2016-01-15 | 2018-12-10 | Pfizer | Ligandos d3 de dopamina 6,7,8,9-tetrahidro-5h-pirido[2,3-d]azepina . |
| LT3658552T (lt) | 2017-07-28 | 2023-11-27 | Yuhan Corporation | N-(5-((4-(4-((dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il) amino)-4-metoksi-2-morfolinofenil)akrilamido gamybos būdas, vykdant reakciją tarp atitinkamo amino ir 3-halogen-propionilo chlorido |
| EP3670500A4 (en) * | 2017-08-18 | 2020-12-16 | Beijing Hanmi Pharmaceutical Co., Ltd. | CHEMICAL COMPOUND, PHARMACEUTICAL COMPOSITION OF IT, CORRESPONDING USE AND APPLICATION |
| CN110240545B (zh) * | 2018-03-08 | 2022-04-26 | 迈克斯(如东)化工有限公司 | 一种2-(5-氟-2,4-二硝基苯氧)乙酸的制备方法 |
| TWI674931B (zh) * | 2018-03-13 | 2019-10-21 | 川尚股份有限公司 | 污染混合物的處理方法 |
| JP7149089B2 (ja) * | 2018-03-26 | 2022-10-06 | 株式会社日本触媒 | 含窒素複素環化合物およびスクアリリウム化合物の製造方法 |
| CN112512597A (zh) | 2018-07-26 | 2021-03-16 | 大日本住友制药肿瘤公司 | 用于治疗与acvr1表达异常相关的疾病的方法以及用于此的acvr1抑制剂 |
| WO2020050241A1 (ja) | 2018-09-04 | 2020-03-12 | 中外製薬株式会社 | ４環性化合物の製造方法 |
| CN109632773B (zh) * | 2019-01-08 | 2021-11-12 | 贵州大学 | 一种二氢硫辛酸琥珀酰转移酶抑制剂的筛选方法 |
| CN114302878A (zh) | 2019-07-03 | 2022-04-08 | 大日本住友制药肿瘤公司 | 酪氨酸激酶非受体1(tnk1)抑制剂及其用途 |
| AU2020372382B2 (en) * | 2019-10-22 | 2023-09-14 | Alphala Co., Ltd. | Pyrimidine amide compounds and use thereof |
| CN110950797A (zh) * | 2019-12-06 | 2020-04-03 | 丽水绿氟科技有限公司 | 一种2-三氟甲基-3-氟-4-吡啶甲酸及其衍生物的制备方法 |
| US20230158157A1 (en) * | 2020-02-25 | 2023-05-25 | Dana-Farber Cancer Institute, Inc. | Potent and selective degraders of alk |
| JP2023522863A (ja) * | 2020-04-14 | 2023-06-01 | 斉魯制薬有限公司 | Ｅｇｆｒ阻害剤としての三環式化合物 |
| EP4163278A1 (en) * | 2020-05-29 | 2023-04-12 | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. | Pyrimidine compound as axl inhibitor |
| CN112213428A (zh) * | 2020-10-13 | 2021-01-12 | 辽宁科技大学 | 一种超临界co2中进行非催化乙酰基化反应及其在线检测方法 |
| CN116981664A (zh) * | 2021-01-07 | 2023-10-31 | 安大略省癌症研究所(Oicr) | 作为nuak激酶的抑制剂的噻吩基和环烷基氨基嘧啶化合物、其组合物和用途 |
| CN116768888A (zh) * | 2021-03-23 | 2023-09-19 | 杭州阿诺生物医药科技有限公司 | Hpk1激酶抑制剂化合物 |
| EP4320153A1 (en) | 2021-04-09 | 2024-02-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of anaplastic large cell lymphoma |
| CN115838383A (zh) * | 2021-09-22 | 2023-03-24 | 南京正大天晴制药有限公司 | 作为axl抑制剂的苯并环庚烷类化合物 |
| TW202317117A (zh) * | 2021-10-14 | 2023-05-01 | 大陸商齊魯製藥有限公司 | 一種三環化合物的用途 |
| CN114133360A (zh) * | 2021-11-30 | 2022-03-04 | 南京工业大学 | 一种含氟苯并[d]-1,3-氧氮杂卓化合物及其合成方法 |
| CN114539104A (zh) * | 2022-03-09 | 2022-05-27 | 常州佳德医药科技有限公司 | 一种艾拉莫德中间体的制备方法 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999005107A1 (en) | 1997-07-25 | 1999-02-04 | Smithkline Beecham Corporation | Vitronectin receptor antagonist |
| DE69905306T2 (de) * | 1998-03-27 | 2003-11-27 | Janssen Pharmaceutica Nv | HIV hemmende Pyrimidin Derivate |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
| US6906067B2 (en) | 1999-12-28 | 2005-06-14 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-α expression |
| GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| CN100480242C (zh) | 2001-05-29 | 2009-04-22 | 舍林股份公司 | Cdk抑制性嘧啶化合物、其制备方法以及作为药物的应用 |
| JP4510442B2 (ja) | 2001-06-26 | 2010-07-21 | ブリストル−マイヤーズ スクイブ カンパニー | ＴＮＦ−α発現のＮ−ヘテロ環インヒビター |
| US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
| US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| WO2003026664A1 (en) | 2001-09-26 | 2003-04-03 | Bayer Corporation | 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors |
| EP2332924A1 (de) | 2001-10-17 | 2011-06-15 | Boehringer Ingelheim Pharma GmbH & Co. KG | Pyrimidinderivate, Arzneimittel enthaltend diese Verbindungen, deren Verwendung und Verfahren zu ihrer Herstellung |
| EP1453516A2 (de) | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren |
| BR0213790A (pt) | 2001-11-01 | 2004-12-07 | Janssen Pharmaceutica Nv | Derivados de aminobenzamida como inibidores de glicogênio sintase cinase 3beta |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| AU2002367172A1 (en) | 2001-12-21 | 2003-07-15 | Bayer Pharmaceuticals Corporation | 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
| TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| DE60332433D1 (de) | 2002-03-15 | 2010-06-17 | Vertex Pharma | Azolylaminoazine als proteinkinasehemmer |
| ATE468336T1 (de) | 2002-03-15 | 2010-06-15 | Vertex Pharma | Azolylaminoazine als proteinkinasehemmer |
| ATE433973T1 (de) | 2002-03-15 | 2009-07-15 | Vertex Pharma | Azolylaminoazine als inhibitoren von proteinkinasen |
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| AU2003231231A1 (en) | 2002-05-06 | 2003-11-11 | Bayer Pharmaceuticals Corporation | Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders |
| WO2004002964A1 (ja) | 2002-06-28 | 2004-01-08 | Yamanouchi Pharmaceutical Co., Ltd. | ジアミノピリミジンカルボキサミド誘導体 |
| NZ537752A (en) | 2002-07-29 | 2006-12-22 | Rigel Pharmaceuticals Inc | Use of 2,4-pyrimidinediamine compounds in the preparation of medicaments for treating autoimmune diseases |
| EA010727B1 (ru) | 2003-02-26 | 2008-10-30 | Суджен, Инк. | Аминогетероарильные соединения в качестве ингибиторов протеинкиназ |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| US7504396B2 (en) | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| US7037909B2 (en) | 2003-07-02 | 2006-05-02 | Sugen, Inc. | Tetracyclic compounds as c-Met inhibitors |
| CA2529622A1 (en) | 2003-07-02 | 2005-01-20 | Sugen, Inc. | Indolinone hydrazides as c-met inhibitors |
| US7122548B2 (en) | 2003-07-02 | 2006-10-17 | Sugen, Inc. | Triazolotriazine compounds and uses thereof |
| WO2005006945A2 (en) | 2003-07-03 | 2005-01-27 | The Salk Institute For Biological Studies | Methods for treating neural disorders and compounds useful therefor |
| JP4836788B2 (ja) | 2003-07-23 | 2011-12-14 | エグゼリクシス， インコーポレイテッド | 未分化リンパ腫キナーゼ変調因子及びその使用法 |
| US7442698B2 (en) | 2003-07-24 | 2008-10-28 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| ES2421139T3 (es) | 2003-07-30 | 2013-08-29 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias |
| DE602004032446D1 (de) | 2003-08-07 | 2011-06-09 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel |
| WO2005016894A1 (en) | 2003-08-15 | 2005-02-24 | Novartis Ag | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
| TWI339206B (en) | 2003-09-04 | 2011-03-21 | Vertex Pharma | Compositions useful as inhibitors of protein kinases |
| GB0321710D0 (en) * | 2003-09-16 | 2003-10-15 | Novartis Ag | Organic compounds |
| US20070105839A1 (en) | 2003-09-18 | 2007-05-10 | Patricia Imbach | 2, 4-Di (phenylamino) pyrimidines useful in the treatment of proliferative disorders |
| PL2210607T3 (pl) | 2003-09-26 | 2012-01-31 | Exelixis Inc | N-[3-fluoro-4-({6-(metyloksy)-7-[(3-morfolin-4-ylopropylo)oksy]chinolin-4-ylo} oxy)fenylo]-N'-(4-fluorofenylo)cyklopropano-1,1-dikarboksamid do leczenia raka |
| US7144889B2 (en) | 2003-10-16 | 2006-12-05 | Hoffman-La Roche Inc. | Triarylimidazoles |
| US7169781B2 (en) | 2003-10-17 | 2007-01-30 | Hoffmann-La Roche Inc. | Imidazole derivatives and their use as pharmaceutical agents |
| EP1694652A1 (en) | 2003-12-19 | 2006-08-30 | Rigel Pharmaceuticals, Inc. | Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates |
| BRPI0507373A (pt) | 2004-01-23 | 2007-07-10 | Amgen Inc | compostos e método de uso |
| CN1918158B (zh) | 2004-02-14 | 2011-03-02 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
| EP1720574A4 (en) | 2004-02-23 | 2009-09-09 | Sugen Inc | METHOD OF TREATING ABNORMAL CELL GROWTH USING C-MET AND M-TOR INHIBITORS |
| EP1730128A1 (en) | 2004-03-31 | 2006-12-13 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| TW200538453A (en) | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
| MXPA06013164A (es) | 2004-05-14 | 2007-02-13 | Pfizer Prod Inc | Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal. |
| JP2007537238A (ja) | 2004-05-14 | 2007-12-20 | ファイザー・プロダクツ・インク | 異常細胞増殖の治療のためのピリミジン誘導体 |
| WO2005118544A2 (en) | 2004-05-18 | 2005-12-15 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
| EP1598343A1 (de) | 2004-05-19 | 2005-11-23 | Boehringer Ingelheim International GmbH | 2-Arylaminopyrimidine als PLK Inhibitoren |
| US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| GB0419161D0 (en) | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| GB0419160D0 (en) | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| GB2420559B (en) | 2004-11-15 | 2008-08-06 | Rigel Pharmaceuticals Inc | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses |
| AU2005322855B2 (en) | 2004-12-30 | 2012-09-20 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
| WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
| JP5225079B2 (ja) | 2005-06-08 | 2013-07-03 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｊａｋ経路の阻害のための組成物および方法 |
| US20070032514A1 (en) | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
| KR20080027832A (ko) | 2005-07-11 | 2008-03-28 | 사노피-아벤티스 | 신규의 2,4-디아닐리노피리미딘 유도체, 그의 제법, 및의약으로서, 제약 조성물로서, 특히 ｉｋｋ 억제제로서의그의 용도 |
| WO2007028445A1 (en) | 2005-07-15 | 2007-03-15 | Glaxo Group Limited | 6-indolyl-4-yl-amino-5-halogeno-2-pyrimidinyl-amino derivatives |
| KR100674813B1 (ko) | 2005-08-05 | 2007-01-29 | 일양약품주식회사 | Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법 |
| AU2006309013B2 (en) | 2005-11-01 | 2012-06-28 | Impact Biomedicines, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| JP4332590B2 (ja) * | 2005-12-21 | 2009-09-16 | ファイザー・プロダクツ・インク | 異常細胞増殖を治療するためのピリミジン誘導体 |
| TW200736232A (en) * | 2006-01-26 | 2007-10-01 | Astrazeneca Ab | Pyrimidine derivatives |
| EA200870217A1 (ru) | 2006-01-30 | 2009-02-27 | Экселиксис, Инк. | 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции |
| US7569561B2 (en) | 2006-02-22 | 2009-08-04 | Boehringer Ingelheim International Gmbh | 2,4-diaminopyrimidines useful for treating cell proliferation diseases |
| US8258129B2 (en) | 2006-07-06 | 2012-09-04 | Boehringer Ingelheim International Gmbh | 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments |
| WO2008051547A1 (en) * | 2006-10-23 | 2008-05-02 | Cephalon, Inc. | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors |
| NZ577197A (en) | 2006-12-08 | 2011-02-25 | Irm Llc | Pyrimidine compounds especially 4-phenylamino-2-arylamino-pyrimidine derivatives and compositions as protein kinase inhibitors |
| DK2091918T3 (en) | 2006-12-08 | 2014-12-01 | Irm Llc | Compounds and Compositions as Protein Kinase Inhibitors |
-
2007
- 2007-10-23 WO PCT/US2007/022496 patent/WO2008051547A1/en active Application Filing
- 2007-10-23 EP EP13173365.1A patent/EP2684874B1/en active Active
- 2007-10-23 TW TW096139772A patent/TWI432427B/zh not_active IP Right Cessation
- 2007-10-23 EP EP07861484.9A patent/EP2222647B1/en active Active
- 2007-10-23 NZ NZ576425A patent/NZ576425A/xx unknown
- 2007-10-23 AR ARP070104687A patent/AR063527A1/es not_active Application Discontinuation
- 2007-10-23 ES ES07861484.9T patent/ES2555803T3/es active Active
- 2007-10-23 CN CN2007800394641A patent/CN101535276B/zh active Active
- 2007-10-23 US US12/162,851 patent/US8148391B2/en active Active
- 2007-10-23 AU AU2007309427A patent/AU2007309427B2/en active Active
- 2007-10-23 MX MX2009004426A patent/MX2009004426A/es active IP Right Grant
- 2007-10-23 CL CL200703049A patent/CL2007003049A1/es unknown
- 2007-10-23 JP JP2009534629A patent/JP5512274B2/ja active Active
- 2007-10-23 ES ES13173365.1T patent/ES2633318T3/es active Active
- 2007-10-23 CA CA2669111A patent/CA2669111C/en active Active
-
2009
- 2009-04-16 IL IL198150A patent/IL198150A/en active IP Right Grant
-
2011
- 2011-02-24 HK HK11101845.2A patent/HK1147748A1/xx unknown
-
2012
- 2012-03-06 US US13/413,322 patent/US8552186B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2669111A1 (en) | 2008-05-02 |
| AU2007309427A1 (en) | 2008-05-02 |
| TW200833686A (en) | 2008-08-16 |
| US8148391B2 (en) | 2012-04-03 |
| CA2669111C (en) | 2016-04-12 |
| EP2222647A1 (en) | 2010-09-01 |
| TWI432427B (zh) | 2014-04-01 |
| EP2222647B1 (en) | 2015-08-05 |
| US8552186B2 (en) | 2013-10-08 |
| IL198150A (en) | 2014-06-30 |
| US20090221555A1 (en) | 2009-09-03 |
| EP2684874A1 (en) | 2014-01-15 |
| WO2008051547A1 (en) | 2008-05-02 |
| ES2633318T3 (es) | 2017-09-20 |
| JP2010507665A (ja) | 2010-03-11 |
| NZ576425A (en) | 2012-04-27 |
| CN101535276B (zh) | 2013-08-28 |
| ES2555803T3 (es) | 2016-01-08 |
| AR063527A1 (es) | 2009-01-28 |
| MX2009004426A (es) | 2009-08-12 |
| IL198150A0 (en) | 2009-12-24 |
| AU2007309427B2 (en) | 2013-02-28 |
| JP5512274B2 (ja) | 2014-06-04 |
| EP2684874B1 (en) | 2017-05-17 |
| CN101535276A (zh) | 2009-09-16 |
| US20120165519A1 (en) | 2012-06-28 |
| HK1147748A1 (en) | 2011-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2007003049A1 (es) | Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos. | |
| ES2964858T3 (es) | Proceso para la preparación de 2,3,3,3-tetrahidrofluoropropeno | |
| BRPI0909768A2 (pt) | composto, composição farmacêutica, método para o tratamento ou prevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto""composto, composição farmacêutica, método para o tratamento ou orevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto | |
| CL2007003849A1 (es) | Compuestos derivados de nafto[c]pirrol sustituidos con aminoacidos, utiles para tratar el cancer. | |
| BRPI0819218A2 (pt) | Métodos, estojos e composições para administração de compostos farmacêuticos | |
| CL2007003226A1 (es) | Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer. | |
| CL2007002650A1 (es) | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. | |
| CL2008000789A1 (es) | Compuestos derivados de adenina; composicion farmaceutica que comprende a dichos compuestos, utiles para tratar enfermedades alergicas, virales o cancer, entre otras. | |
| CL2007003758A1 (es) | Compuestos derivados de aminopirimidina, inhibidores de plk1; composicion farmaceutica, util para el tratamiento de cancer. | |
| BRPI0816881A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto. | |
| CL2007002578A1 (es) | Compuestos derivados de n-(1-ftalazin-1-il-piperidin-4-il)-amidas; composicion farmaceutica; y uso para el tratamiento y prevencion de trastornos de la fertilidad, osteoporosis y cancer. | |
| BRPI0810646A2 (pt) | " compostos farmacêuticos ". | |
| CL2007001040A1 (es) | Proceso para la preparacion de antagonista de la sustancia p derivado de acil-amino-alquilen-amida. | |
| CL2007003341A1 (es) | Compuestos derivados de imidazotriazinas; composicion farmaceutica, util para el tratamiento del cancer, arteroesclerosis y enfermedades cardiovasculares entre otras. | |
| BRPI0818732A2 (pt) | Composições de análogo de prostaglandina e métodos para tratar condições relacionadas epiteliais. | |
| CL2007003854A1 (es) | Compuestos derivados de ciclopamina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto, util en el tratamiento de desordenes mediados por la via de hedgehog, como cancer. | |
| BRPI0814958A2 (pt) | Compostos de indazol ou indol, composição, e, método para preparar uma composição. | |
| CL2007002920A1 (es) | Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos. | |
| CL2007003832A1 (es) | Compuestos derivados de azaespiro; procedimiento de preparacion; composicion farmaceutica; y su uso para prevenir y tratar ansiedad, trastornos depresivos, entre otras enfermedades. | |
| BRPI0816784A2 (pt) | Fatores neuro-endócrinos para o tratamento de doenças degenerativas | |
| CL2008000403A1 (es) | Compuestos derivados de pentafluorotiobenzamido-acetonitrilo; composicion farmaceutica; y uso para tratar una infestacion por parasitos. | |
| CL2007003265A1 (es) | Compuestos derivados de 1h-piran[2,3-d]pirimidin-2,4,7-triona; y composicion farmaceutica, util para el tratamiento de sindrome metabolico, dislipidemia y enfermedades cardiovasculares entre otras. | |
| BRPI0719398A2 (pt) | Composição farmacêutica. | |
| BRPI0615163A2 (pt) | composto, composição farmacêutica, uso do composto, e, métodos de tratamento de distúrbios mediados por mglur5 e para inibição da ativação de receptores de mglur5 | |
| BRPI0815591A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença, condição ou distúrbio. |